[Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases].

Abstract

A global improvement rate ("markedly improved" + " moderately improved") of 66% was obtained and SPG was regarded as safe in 85% of patients and useful or very useful in 82%. SPG is expected to be a useful new therapy for Raynaud's phenomenon in patients with collagen disease.